Liraglutide briefing documents now available for the FDA Advisory 
Committee meeting on 2 April 
 
 
Novo Nordisk announced today that the United States Food and Drug 
Administration (FDA) has made liraglutide briefing documents publicly 
available on its website (www.fda.gov) ahead of the Endocrinologic 
and Metabolic Drugs Advisory Committee public meeting on 2 April 
2009. This is a common procedure in connection with advisory 
committee meetings. 
 
The briefing documents from Novo Nordisk and the FDA provide an 
overview of the non-clinical and clinical data for liraglutide in the 
treatment of type 2 diabetes and will form the basis for the Advisory 
Committee's discussion. The Novo Nordisk briefing document contains 
data from 40 clinical studies involving more than 6,800 people with 
type 2 diabetes of which more than 4,600 were treated with 
liraglutide. 
 
The Advisory Committee is expected to make recommendations to the FDA 
on questions related to the approval of liraglutide for the treatment 
of type 2 diabetes based on the overall benefit:risk profile of 
liraglutide. 
FDA advisory committees are panels of independent experts who advise 
the FDA as they consider regulatory decisions. 
 
Conference call 
On 3 April at 8 am CET, corresponding to 2 am EDT, a conference call 
for investors will be held. Investors will be able to listen in via a 
link on the investor section of novonordisk.com. 
 
About liraglutide 
Liraglutide is the first once-daily human Glucagon-Like Peptide-1 
(GLP-1) analogue developed for the treatment of type 2 diabetes. 
Liraglutide works by stimulating the release of insulin only when 
glucose levels become too high and by inhibiting appetite. On 23 May 
2008, Novo Nordisk submitted a New Drug Application to the Food and 
Drug Administration in the US as well as a marketing authorisation 
application to the European Medicines Agency in Europe, for the 
approval of liraglutide for the treatment of people with type 2 
diabetes. A New Drug Application was also submitted for approval in 
Japan on 15 July 2008. 
 
Novo Nordisk is a healthcare company and a world leader in diabetes 
care. In addition, Novo Nordisk has a leading position within areas 
such as haemostasis management, growth hormone therapy and hormone 
replacement therapy. Novo Nordisk manufactures and markets 
pharmaceutical products and services that make a significant 
difference to patients, the medical profession and society. With 
headquarters in Denmark, Novo Nordisk employs more than 27,000 
employees in 81 countries, and markets its products in 179 countries. 
Novo Nordisk's B shares are listed on the stock exchanges in 
Copenhagen and London. Its ADRs are listed on the New York Stock 
Exchange under the symbol 'NVO'. For more information, visit 
novonordisk.com. 
 
Contacts for further information: 
 
Media:                 Investors: 
 
Mike Rulis             Mads Veggerby Lausten 
Tel: (+45) 4442 3573   Tel: (+45) 4443 7919 
mike@novonordisk.com   mlau@novonordisk.com 
 
                       Kasper Roseeuw Poulsen 
                       Tel: (+45) 4442 4471 
                       krop@novonordisk.com 
 
In North America:      In North America: 
An Phan                Hans Rommer 
Tel: (+1) 609 558 0420 Tel: (+1) 609 919 7937 
anph@novonordisk.com   hrmm@novonordisk.com 
 
 
Company Announcement no 18 / 2009 
 
 
This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement. 
 
http://hugin.info/2013/R/1301982/297817.pdf 
http://novonordisk.com 
Copyright © Hugin AS 2009. All rights reserved.